Portal de Periódicos da CAPES

Acute renal haemodynamic effects of glucagon‐like peptide‐1 receptor agonist exenatide in healthy overweight men

2015; Wiley; Volume: 18; Issue: 2 Linguagem: Inglês

10.1111/dom.12601

1463-1326

Marcel H.A. Muskiet, Lennart Tonneijck, Mark M. Smits, Mark H.H. Kramer, M. Diamant, Jaap A. Joles, Daniël H. van Raalte,

Blood Pressure and Hypertension Studies

Aims To determine the acute effect of glucagon‐like peptide‐1 ( GLP‐1 ) receptor agonist exenatide and the involvement of nitric oxide ( NO ) on renal haemodynamics and tubular function, in healthy overweight men. Methods Renal haemodynamics and tubular electrolyte handling were measured in 10 healthy overweight men (aged 20–27 years; BMI 26–31 kg/m 2 ) during intravenous administration of placebo (saline 0.9%), exenatide, and exenatide combined with the NO ‐synthase inhibitor L‐N G ‐monomethyl arginine ( L‐NMMA ). Glomerular filtration rate ( GFR ) and effective renal plasma flow ( ERPF ) were determined by inulin and para‐aminohippurate clearance techniques, respectively, based on timed urine sampling. Glomerular hydrostatic pressure and vascular resistance of afferent and efferent renal arterioles were calculated using the G omez formulae. Urinary electrolytes, osmolality and pH were also measured. Results GFR increased by a mean of 18 ± 20 (+20%; p = 0.021) and ERPF increased by a median (interquartile range) of 68 (26; 197) ml/min/1.73 m 2 (+14%; p = 0.015) during exenatide infusion versus placebo. During L‐NMMA infusion, exenatide increased GFR by mean 8 ± 12 ml/min/1.73 m 2 (+9%; p = 0.049). Exenatide increased estimated glomerular pressure by +6% (p = 0.015) and reduced afferent renal vascular resistance by −33% (p = 0.038), whereas these effects were blunted during L‐NMMA infusion. Exenatide increased absolute and fractional sodium excretion, urinary osmolality and urinary pH . The tubular effects of exenatide were not altered by concomitant L‐NMMA infusion. Conclusions Exenatide infusion in healthy overweight men acutely increases GFR , ERPF and glomerular pressure, probably by reducing afferent renal vascular resistance, and at least partially in an NO ‐dependent manner. As baseline renal haemodynamics in patients with type 2 diabetes differ from those in healthy individuals, clinical studies on the renal effects of GLP‐1 receptor agonists are warranted.